Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2020 | Story Andre Damons | Photo Barend Nagel
Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), has been appointed as the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), will lead Africa’s fight against the COVID-19 pandemic with his appointment as chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Matsabisa has been chosen over 25 other experts from 27 African countries to head this expert committee tasked with setting up research and clinical trials for COVID-19 and beyond. The committee is also supported by the African Union (AU), the Centers for Disease Control and Prevention (CDC – Africa), and the European and Developing Countries Clinical Trials Partnership (EDCTP).

This committee was established by the WHO and the Africa CDC on 22 July with the aim of providing independent scientific advice and support to countries on the safety, efficacy, and quality of traditional medicine therapies. It is also an effort to enhance research and development of traditional medicines for COVID-19 in Africa.

Looking forward

“This is a huge continental and global responsibility being laid on my shoulders as a chairperson.  I have to keep the committee together and ensure that it delivers on its set mandate and terms of reference.  I need to ensure that the committee helps the continent and region to get the scientific and legislative aspects on traditional medicine development on track.”  

“I have taken this position and responsibility, knowing quite well what it entails. I want to do this for the continent and for the sake of good science of all traditional healers and consumers of traditional medicines on the continent and beyond,” says Prof Matsabisa.

According to Prof Matsabisa, he is looking forward to working with a team of dedicated experts from 27 countries in the African region, and being of help to countries that need assistance with clinical trials, including preclinical work to move to clinical research.

Prof Matsabisa says he is also looking forward to countries asking South Africa to be part of their multi-centre studies in clinical trials for traditional medicines, and to help set up clinical trial teams that include Western-trained clinicians to get into traditional medicine studies. 

The work of the committee

According to Prof Matsabisa, his new position took effect the same day as his appointment and will run as long as COVID-19 is part of our daily lives and even beyond. It entails supporting member states to implement the WHO master plan for clinical trial protocols in order to generate credible data for COVID-19 results, based on traditional medicines. The committee will also coordinate support to member states in the African region to collaborate on clinical trials of traditional medicine-based therapies – elevating standards by pooling expertise in multicentre studies, as well as complying with GCP and good participatory practice guidelines for trials of emerging and re-emerging pathogens.
“The committee will also advise on strengthening the capacity of national medicine regulatory authorities to accelerate the issuance of marketing authorisations for traditional medicine products that have been well researched for safety, efficacy, and quality, as well as to expedite the approval of clinical trials on traditional medicines. This will help to meet the national registration criteria and the WHO norms and standards of quality, safety, and efficacy for the management of COVID-19 and others.”

“It will also provide independent scientific advice to the WHO and other partners regarding policies, strategies, and plans for integrating traditional medicines into COVID-19 responses and health systems,” explains Prof Matsabisa. 

Aiming for the top spot 

Prof Matsabisa has been described as having the third highest research output – something he is not satisfied with. 
“I was disappointed that only one point separated me from the second place. I will push for first place as this is my ultimate aim. My motivation for this is simple – I like what I am doing, I do not take it as a job but do it because I love research.”  

“I always like to tell students that we should be proud to one day see products in the shops that we can relate to and to which we have contributed or that we have made.   This is what drives me and my staff.  I have a beautiful team of students, staff, and postdoctoral fellows who share my vision of research.  We all have a shared vision and strive to be relevant at all times in science research, development, and teaching.”

• Prof Matsabisa was recently part of a national conference with the theme: Harnessing science, technology, and innovation in response to COVID-19: A national and international effort. The conference was hosted by Dr Blade Nzimande, Minister of Higher Education, Science and Innovation, with Pres Cyril Ramaphosa, Dr Zweli Mkhize, Minister of Health, Ebrahim Patel, Minister of Trade, Industry and Competition, Prof Sarah Anyang Agbor, African Union Commissioner for Human Resources, Science and Technology, and Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation, in attendance. 

News Archive

Higher than expected prevalence of dementia in South African urban black population
2010-09-22

 Prof. Malan Heyns and Mr Rikus van der Poel

Pilot research done by University of the Free State (UFS) indicates that the prevalence of dementia, of which Alzheimer’s disease is only one of the causes, is considerably higher than initially estimated. Clinical tests are now underway to confirm these preliminary findings.

To date it has been incorrectly assumed that dementia is less prevalent among urban black communities. This assumption is strongly disputed by the findings of the current study, which indicates a preliminary prevalence rate of approximately 6% for adults aged 65 years and older in this population group. Previous estimates for Southern Africa have been set at around 2,1%.

The research by the Unit for Professional Training and Services in the Behavioural Sciences (UNIBS) at the UFS and Alzheimer’s South Africa is part of the International 10/66 Dementia Research Group’s (10/66 DRG) initiative to establish the prevalence of dementia worldwide.

Mr Rikus van der Poel, coordinator of the local study, and Prof. Malan Heyns, Principal Investigator, say worldwide 66% of people with dementia live in low and middle income countries. It is expected that it will rise to more than 70% by 2040, and the socio-economic impact of dementia will increase accordingly within this period. 21 September marks World Alzheimer’s Day, and this year the focus is on the global economic impact of dementia. Currently, the world wide cost of dementia exceeds 1% of the total global GDP. If the global cost associated with dementia care was a company, it would be larger than Exxon-Mobil or Wal-Mart.

The researchers also say that of great concern is the fact that South Africa’s public healthcare system is essentially geared toward addressing primary healthcare needs, such as HIV/Aids and tuberculosis. The adult prevalence rate of HIV was 18,1% in 2007. According to UNAIDS figures more than 5,7 million people in South Africa are living with HIV/Aids, with an estimated annual mortality of 300 000. In many instances the deceased are young parents, with the result that the burden of childcare falls back on the elderly, and in many cases elderly grandparents suffering from dementia are left without children to take care of them. “These are but a few reasons that highlight the need for advocacy and awareness regarding dementia and care giving in a growing and increasingly urbanized population,” they say.

Low and middle income countries often lack epidemiological data to provide representative estimates of the regional prevalence of dementia. In general, epidemiological studies are challenging and expensive, especially in multi-cultural environments where the application of research protocols relies heavily on accurate language translations and successfully negotiated community access. Despite these challenges, the local researchers are keen to support advocacy and have joined the international effort to establish the prevalence of dementia through the 10/66 DRG.

The 10/66 DRG is a collective of researchers carrying out population-based research into dementia, non-communicable diseases and ageing in low and middle income countries. 10/66 refers to the two-thirds (66%) of people with dementia living in low and middle income countries, and the 10% or less of population-based research that has been carried out in those regions.

Since its inception in 1998, the 10/66 DRG has conducted population based surveys in 14 catchment areas in ten low and middle income countries, with a specific focus on the prevalence and impact of dementia. South Africa is one of seven LAMICs (low and medium income countries) where new studies have been conducted recently, the others being Puerto Rico, Peru, Mexico, Argentina, China and India.

Mr Van der Poel says participating researchers endeavour to conduct cross-sectional, comprehensive, one-phase surveys of all residents aged 65 and older within a geographically defined area. All centres share the same core minimum dataset with cross-culturally validated assessments (dementia diagnosis and subtypes, mental disorders, physical health, anthropometry, demographics, extensive non-communicable risk factor questionnaires, disability/functioning, health service utilization and caregiver strain).

The local pilot study, funded by Alzheimer’s South Africa, was rolled out through an existing community partnership, the Mangaung University of the Free State Community Partnership Programme (MUCPP).

According to Mr Van der Poel and Prof. Heyns, valuable insights have been gained into the myriad factors at play in establishing an epidemiological research project. The local community has responded positively and the pilot phase in and of itself has managed to promote awareness of the condition. The study has also managed to identify traditional and culture-specific views of dementia and dementia care. In addition, existing community-based networks are being strengthened, since part of the protocol will include the training and development of family caregivers within the local community in Mangaung.

“Like most developing economies, the South African population will experience continued urbanization during the next two decades, along with increased life expectancy. Community-based and residential care facilities for dementia are few and far between and government spending will in all probability continue to address the high demands associated with primary healthcare needs. These are only some of the reasons why epidemiological and related research is an important tool for assisting lobbyists, advocates and policymakers in promoting better care for those affected by dementia.”

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za  
21 September 2010

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept